Literature DB >> 18247608

High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: nanosized MRI contrast agents.

Ankona Datta1, Jacob M Hooker, Mauro Botta, Matthew B Francis, Silvio Aime, Kenneth N Raymond.   

Abstract

High relaxivity macromolecular contrast agents based on the conjugation of gadolinium chelates to the interior and exterior surfaces of MS2 viral capsids are assessed. The proton nuclear magnetic relaxation dispersion (NMRD) profiles of the conjugates show up to a 5-fold increase in relaxivity, leading to a peak relaxivity (per Gd3+ ion) of 41.6 mM(-1) s(-1) at 30 MHz for the internally modified capsids. Modification of the exterior was achieved through conjugation to flexible lysines, while internal modification was accomplished by conjugation to relatively rigid tyrosines. Higher relaxivities were obtained for the internally modified capsids, showing that (i) there is facile diffusion of water to the interior of capsids and (ii) the rigidity of the linker attaching the complex to the macromolecule is important for obtaining high relaxivity enhancements. The viral capsid conjugated gadolinium hydroxypyridonate complexes appear to possess two inner-sphere water molecules (q = 2), and the NMRD fittings highlight the differences in the local motion for the internal (tauRl = 440 ps) and external (tauRl = 310 ps) conjugates. These results indicate that there are significant advantages of using the internal surface of the capsids for contrast agent attachment, leaving the exterior surface available for the installation of tissue targeting groups.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18247608     DOI: 10.1021/ja0765363

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  60 in total

1.  Strategies for the preparation of bifunctional gadolinium(III) chelators.

Authors:  Luca Frullano; Peter Caravan
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

Review 2.  Lanthanide probes for bioresponsive imaging.

Authors:  Marie C Heffern; Lauren M Matosziuk; Thomas J Meade
Journal:  Chem Rev       Date:  2013-12-13       Impact factor: 60.622

Review 3.  The art of engineering viral nanoparticles.

Authors:  Jonathan K Pokorski; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2010-12-17       Impact factor: 4.939

Review 4.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 5.  Virus-Based Nanoparticles as Versatile Nanomachines.

Authors:  Kristopher J Koudelka; Andrzej S Pitek; Marianne Manchester; Nicole F Steinmetz
Journal:  Annu Rev Virol       Date:  2015-09-25       Impact factor: 10.431

Review 6.  Environmentally responsive MRI contrast agents.

Authors:  Gemma-Louise Davies; Iris Kramberger; Jason J Davis
Journal:  Chem Commun (Camb)       Date:  2013-10-28       Impact factor: 6.222

7.  Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents.

Authors:  Michael A Bruckman; Stephen Hern; Kai Jiang; Chris A Flask; Xin Yu; Nicole F Steinmetz
Journal:  J Mater Chem B       Date:  2013-03-14       Impact factor: 6.331

Review 8.  Modified natural nanoparticles as contrast agents for medical imaging.

Authors:  David P Cormode; Peter A Jarzyna; Willem J M Mulder; Zahi A Fayad
Journal:  Adv Drug Deliv Rev       Date:  2009-11-06       Impact factor: 15.470

9.  Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles.

Authors:  Gary J Tong; Sonny C Hsiao; Zachary M Carrico; Matthew B Francis
Journal:  J Am Chem Soc       Date:  2009-08-12       Impact factor: 15.419

10.  Conjugation to Biocompatible Dendrimers Increases Lanthanide T2 Relaxivity of Hydroxypyridinone (HOPO) Complexes for Magnetic Resonance Imaging (MRI).

Authors:  Piper J Klemm; William C Floyd; Christopher M Andolina; Jean M J Fréchet; Kenneth N Raymond
Journal:  Eur J Inorg Chem       Date:  2012-04       Impact factor: 2.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.